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1. Introduction
This text is now the third volume in a series of books focused on extracorporeal 
membrane oxygenation (ECMO) and extracorporeal life support (ECLS) [1]. 
With each volume, it becomes clearer that there has been a rapid evolution in the 
technology and the applications of it with regard to indications, management, 
outcomes, and the challenges in offering a very resource-intensive (and expensive) 
therapy in which the overall benefits are still questioned. Nevertheless, without 
a doubt, there has been an ongoing evolution of the use of ECMO as a salvage 
therapy offered only in extreme and potentially inherently futile cases, to now a 
mainstream therapy that can be routinely offered in well-defined cases of acute 
cardiac and respiratory failure. Early experiences resulted in few survivors and 
poor outcomes, but the reasons for this were clearly complex and multifactorial 
etiologies [2]. The development of more advanced pumps and circuits, better 
resources and guidelines for patient selection and management, and a broader 
understanding of the complex interactions between humans and an extracorporeal 
pump circuit for longer periods of time all have contributed to the advances in 
ECMO as an appropriate and reasonable therapy—even, as some would debate, 
standard of care for acute respiratory failure and/or cardiogenic shock. As these 
three volumes illustrate, over the years, there has been tireless improvements in all 
aspects of the use of ECMO. However, as the chapters in this text clearly illustrate, 
there is still much to be learned and understood. Challenges remain as clinicians 
continue to push the envelope of this technology to better define a patient popula-
tion that might benefit from ECMO and how to apply and manage a very complex 
therapy to optimize outcomes [3].
As the indications for therapy evolve, there continues to be unusual and chal-
lenging clinical situations that deserve special attention for many reasons. For 
example, the chapter by Professor Nandini highlights the very complex issue that 
is becoming more common—the role of ECMO as a bridge to transplant. It was 
only a few years ago (and illustrated in the previous texts in this series) that the 
concept of ECMO as bridge to transplant was discouraged and difficult to justify 
due to the risks, concerns of limited resource allocation, and technical difficulties 
to a concept and management pathway that is routinely considered and offered to 
selected patients.
Additional chapters focus on the growing literature and experiences in other 
specific disease state or clinical situations for which ECMO might be considered. 
Advances in Extracorporeal Membrane Oxygenation - Volume 3
2
One area that is particularly challenging is incorporating ECMO into the manage-
ment of patients who develop acute cardiopulmonary collapse. ECMO-assisted 
CPR (eCPR) is one of the fastest growing uses of ECMO, and many rapid 
response/code teams are increasingly using ECMO in the management of patients 
who develop cardiac arrest. The data, experiences, and outcomes in this very com-
plex area are rapidly evolving, and the controversies are substantial. The chapter 
by Dr. Lakshmi illustrates the current state of the art in this area and how patients 
can be selected and managed, with a focus on illustrating the improved outcomes 
in a patient population that was historically considered unsalvageable. Other 
similar unique applications for ECMO discussed in this text include a chapter 
on carbon dioxide removal by Dr. Morales-Quinteros. The very unusual role of 
normothermic regional perfusion in the setting of solid organ transplantation is 
discussed by Dr. Constantino.
A major focus of this volume is the specific management challenges that 
complicate the use of ECMO, especially in high-risk patient populations. Despite 
a greater awareness, peripheral cannulation techniques that are often used are 
associated with high rates of limb complications including amputation. Such 
concerns are discussed in the chapter by Dr. Prashant. Imaging of patients on 
ECMO, with an emphasis on assessing for cardiac recovery and prognosis, is 
especially important and discussed by Dr. Luigi, while the actual techniques, 
concepts, and applications of various weaning strategies are the focus of another 
chapter. Meanwhile, Dr. Weller’s chapter on anticoagulation in the pediatric 
patient and Dr. Pinto’s chapter on neurologic complications and monitor-
ing revisit some of the difficult topics addressed in the previous editions and 
emphasize the growing experiences and literature in these complex topics [4, 
5]. As some aspects of these topics have been addressed in the earlier books in 
this series, the contemporary experiences highlight that there remains much to 
understand and learn about many of these topics.
Again, it is also clear that to successfully offer ECMO as a viable therapy—
and especially to strive for reasonable outcomes—there must be alignment of all 
key stakeholders. Without a doubt, ECMO requires an extensive team of provid-
ers at all levels working together in a manner that respects professionalism, 
competencies, compassion, and strict attention to details. The substantial and 
tireless efforts of the entire team must be recognized and appreciated by all and 
at all levels [6].
A frequently asked question is “how do we start an ECMO program?” Offering 
ECMO as a therapy involves so much more than just purchasing capital equipment 
and some disposable supplies. The chapter on program development emphasizes 
the many administrative aspects that must be considered within an appropriate 
framework to establish a program. This chapter considers the importance of physi-
cian, nursing, and administrative leadership and collaboration as a foundation for 
a successful program. While a great deal has been written on the extensive medical 
and surgical aspects of the management of a patient on ECMO, the chapter by Mr. 
Botsch and colleagues reviews the many aspects of the nursing bedside care. Of 
course, these topics continue to illustrate the importance of teamwork which cannot 
be overemphasized.
As discussed in the previous editions, a highly functioning “ECMO team” is 
a cornerstone in building a successful program. The ability to initiate therapy 
at any time and place is increasingly considered an important component of a 
well-organized team. While the makeup of an ECMO team can vary across insti-
tutions; each requires a champion to provide leadership and help with structure 
and organization. A fundamental principle is effective communication and a 
multidisciplinary approach to all aspects of management. Just as importantly, all 
3Introductory Chapter: ECMO – Rapidly Evolving Technology, Expanding Indications…
DOI: http://dx.doi.org/10.5772/intechopen.89475
members of the team—regardless of experiences, education, training, degrees, 
and titles—need to have respect and trust and place value on all aspects of the 
contributions of all members. This is the basis of crew resource management 
(CRM). The key concept of CRM is that every team member has input and 
that each voice is valued and respected. Every member of the team needs to be 
empowered to speak up, particularly when there are concerns about safety. The 
different disciplines that are represented in an ECMO Team, as mentioned, can 
vary from program to program, but given the complexities of patient selection 
and management—including, the least of which are the technical aspects of 
cannulation and cannula management—membership must be comprehensive 
with regard to surgical and medical expertise. Membership should include, but 
clearly, not be limited to:
Physicians
• Surgeons (cardiothoracic, general, trauma, emergency medicine)
• Critical care intensivists (pulmonary, surgical)
• Medical specialists (infectious disease, neurology, cardiology, nephrology)
Advanced providers
• Nursing (bedside, advanced practice providers)
• Pharmacists
• Perfusionists
• Respiratory therapists
• Social workers/case management
Palliative care
• Often physician or advance practice nurses
Hospital leadership and administration
• C-suite executives (chief executive, financial, operating, and other officers)
• Quality managers
• Marketing
It is critical that even with dedicated, hardworking, and engaged clinical teams, 
there must be support and encouragement from hospital leadership and administra-
tion (Figure 1) [7].
Many of the chapters in these volumes discuss the various indications for ECMO 
(veno-venous and venoarterial) support and special patient populations and 
circumstances. However, a critical component of any program remains the role of 
striving for optimal clinical outcomes. Regardless of the indications and popula-
tions, outcomes and clinical complications (e.g., renal failure, limb complications, 
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transfusion rates, etc.) must be tracked and compared to published benchmarks. 
Quality conferences in which cases are discussed can help a team and program 
formally recognize their successes while looking for opportunities for collective 
improvement. As discussed previously in the introductions (and various chapters) 
of the previous volumes, outcomes still remain less than ideal with survival rates that 
range from 60 to 70% for veno-venous respiratory support and 25–35% for venoar-
terial cardiopulmonary support and eCPR [8, 9]. These less-than-ideal success rates 
should improve over time as programs gain experience and implement guidelines 
and protocols, teams learn to function more effectively and efficiently, and patient 
selection and management improve. However, poor outcomes must also be tempered 
by the concerns that outcomes that are potentially “too good” might suggest that 
potentially salvageable but higher risk patients might not be offered therapy out 
of fear of experiencing a bad outcome. Nevertheless, it becomes the priority of a 
program to develop a “culture” of how aggressive they want to be with regard to 
offering therapy to high-risk (or low-risk) patients. Fortunately, scoring systems 
for venoarterial and veno-venous support indications can assist in patient selection. 
Again, outcomes and quality metrics must be benchmarked against similar pro-
grams, like institutions and established registries. Membership in the Extracorporeal 
Life Support Organization (ELSO: https://www.elso.org) is an important component 
of tracking outcomes and can play a key role in documenting program progress and 
success. In addition, membership can provide an opportunity to establish relation-
ships with other programs to exchange ideas, share protocols, and have access to 
important and timely developments and technological innovations.
While the advances in the field of ECMO are rapid and there has been an equally 
rapid worldwide growth in programs and the number of patients supported, a key 
aspect of ECMO therapy is the ethical component of a highly invasive, resource-
intensive, and complex intervention. Because ECMO is still associated with less 
than ideal outcomes, relatively high complication rates (including neurologic com-
plications), and high resource intensivity (not to mention expensive, depending 
on the reimbursement circumstances which can vary dramatically), a fundamental 
question remains regarding not on whether we can offer and continue support, but 
Figure 1. 
ECMO “team”. Adopted from reference intro chapter in Volume 1 [1].
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within an ethical and moral framework should we offer support. The chapter by Dr. 
Aultman on the ethics of ECMO therapy explores many of the difficult decisions 
and circumstances that providers often face when considering offering or continu-
ing therapy in patients who would most likely immediately die if support is neither 
offered nor continued.
2. Conclusions
Experiences in the selection and management of patients with acute cardiac and 
respiratory failure who are treated with ECMO continue to grow. Recent trials con-
tinue to help demonstrate the effectiveness and role of ECMO as outcomes continue 
to slowly improve [10, 11]. Even though many patients treated with ECMO still die 
even in the best of circumstances, it remains important for everyone to continue 
to search for opportunities for improvement. Good outcomes must be embraced 
and shared with the entire team, as they can provide hope while also inspiring and 
motivating a team—even when there are concerns of futility (Figure 2). The goal of 
this volume is to offer further insights, experiences, and discussions of the current 
state of the art regarding many topics that challenge those who believed in the 
tremendous potential benefits of ECMO [12].
Figure 2. 
BH (center in wheelchair) with his parents after qualifying for the finals in the single-scull, arms and shoulder 
only, rowing competition in the 2016 Paralympics in Rio de Janeiro. BH, a five-time US national champion in 
the event, represented the USA in Rio as a member of the Olympic team. In 2016, he was selected US rowing 
“rower of the year.” several years prior, BH lost both legs to complications of a necrotizing soft tissue infection 
and required cardiopulmonary support with venoarterial ECMO due to overwhelming septic shock. Picture 
used by permission by all represented [11, 12] and adopted from volume 2 [13].
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